According to the Centers for Disease Control and Prevention’s (CDC) Antibiotic Resistance Threats in the United States report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and at least 35,000 people die as a result of these “superbugs.”

A robust pipeline of novel antimicrobial medicines is necessary for treatments to keep pace with evolving pathogens. With support from Congress, legislation can incentivize researchers to develop new antimicrobial treatments for infections for which there is an unmet medical need, anticipated clinical need, or drug resistance.

Join CQ Roll Call and Pfizer to discuss:

• Patient disease and antimicrobial resistance research
• The PASTEUR Act
• Opportunities to reduce market failures in producing critical antimicrobials

FEATURED SPEAKERS:

• Sen. Todd Young (R-IN) — Co-Sponsor, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act
• Sen. Michael Bennet (D-CO) — Co-Sponsor, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act
• Dr. Michelle McMurry-Heath, President and CEO, Biotechnology Innovation Organization
• Thomas Heymann, President & CEO, Sepsis Alliance
• Dr. Helen Boucher, MD, FACP, FIDSA; Dean ad interim & Professor of Medicine, Tufts University School of Medicine; Chief Academic Officer, Tufts Medicine
• Jessica Wehrman, Health Policy Editor, CQ Roll Call
• Patrick Holmes, Science and Innovation Policy Team Lead, Global Policy and Public Affairs, Pfizer Inc.
• Josh Resnik, Publisher, CQ and Roll Call, President & COO, FiscalNote